Hyperkalemia
Two post-approval outcome trials of anti-hyperkalemia drug stopped for logistical reasons
AstraZeneca announced that two post-approval randomized heart- and kidney-related outcome studies of its anti-hyperkalemia drug have been stopped due to slow enrollment and low event rates.
Long-term use of potassium binder patiromer may slow progression of CKD
Long-term use of the potassium binder patiromer may improve clinical outcomes among patients with chronic kidney disease and hyperkalemia, according to a study.
VIDEO: Rastogi discusses results of treating hyperkalemia with Lokelma
PHILADELPHIA — Treating hyperkalemia with Lokelma (sodium polystyrene sulfonate, AstraZeneca) increased odds of patients maintaining renin-angiotensin-aldosterone system inhibitors therapy, a speaker said.
In HF hospitalization, benefits of sacubitril/valsartan largest in LVEF below normal
Sacubitril/valsartan was associated with reduced natriuretic peptides and lower risk for CV death and HF hospitalization across the spectrum of ejection fraction, particularly in those with EF below 60%, a speaker reported.
Patients with hyperkalemia less likely to receive RAAS inhibitors, have worse HF outcomes
Chinese adults with HF and dyskalemia were less likely to receive renin-angiotensin-aldosterone system inhibitors than patients with normokalemia, and those with hyperkalemia were more likely to experience worsening HF or CV death.
Clinics often pause renin-angiotensin-aldosterone inhibitors in patients with hyperkalemia
Discontinuing or reducing renin-angiotensin-aldosterone system inhibitor treatment may have negative outcomes for patients with hyperkalemia, but it is a common practice in many clinics, according to recently presented research.
Patiromer reduced serum phosphorous, serum potassium in patients with CKD
Treating patients with chronic kidney disease and hyperkalemia with patiromer reduced serum phosphorus and serum potassium levels during a 2-week period, according to data published in the American Journal of Kidney Diseases.
NKF launches public education video series on hyperkalemia
The National Kidney Foundation launched a public education video series about hyperkalemia for patients with chronic kidney disease, according to the press release.
Potassium monitoring device saves money, increases quality of life in patients on dialysis
ORLANDO — Using a real-time potassium monitoring device in patients on hemodialysis saves more money than the usual care and increases quality of life, according to a presenter at ASN Kidney Week.
Dietary potassium intake linked with blood potassium concentration in patients with CKD
Among patients with advanced chronic kidney disease, increasing dietary potassium consumption to recommended levels can increase blood potassium concentration on a short-term basis, according to results of this study.